JP4545929B2 - アゴニストまたはアンタゴニストホルモン特性を有する１７β−アミノおよびヒドロキシルアミノ−１１β−アリルステロイドとその誘導体 - Google Patents

アゴニストまたはアンタゴニストホルモン特性を有する１７β−アミノおよびヒドロキシルアミノ−１１β−アリルステロイドとその誘導体 Download PDF

Info

Publication number
JP4545929B2
JP4545929B2 JP2000552138A JP2000552138A JP4545929B2 JP 4545929 B2 JP4545929 B2 JP 4545929B2 JP 2000552138 A JP2000552138 A JP 2000552138A JP 2000552138 A JP2000552138 A JP 2000552138A JP 4545929 B2 JP4545929 B2 JP 4545929B2
Authority
JP
Japan
Prior art keywords
carbon atoms
alkyl
group
phenyl
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2000552138A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002531381A (ja
Inventor
エドガー・シー・クック
ジョン・エー・ケプラー
ゲリー・エス・バートレイ
ルパ・エス・シェティー
Original Assignee
リサーチ・トライアングル・インスティチュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リサーチ・トライアングル・インスティチュート filed Critical リサーチ・トライアングル・インスティチュート
Publication of JP2002531381A publication Critical patent/JP2002531381A/ja
Application granted granted Critical
Publication of JP4545929B2 publication Critical patent/JP4545929B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
JP2000552138A 1998-05-29 1999-05-28 アゴニストまたはアンタゴニストホルモン特性を有する１７β−アミノおよびヒドロキシルアミノ−１１β−アリルステロイドとその誘導体 Expired - Lifetime JP4545929B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/086,560 1998-05-29
US09/086,560 US6262042B1 (en) 1998-05-29 1998-05-29 17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
PCT/US1999/010480 WO1999062928A1 (en) 1998-05-29 1999-05-28 17β-AMINO AND HYDROXYLAMINO-11β-ARYLSTEROIDS AND THEIR DERIVATIVES HAVING AGONIST OR ANTAGONIST HORMONAL PROPERTIES

Publications (2)

Publication Number Publication Date
JP2002531381A JP2002531381A (ja) 2002-09-24
JP4545929B2 true JP4545929B2 (ja) 2010-09-15

Family

ID=22199388

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000552138A Expired - Lifetime JP4545929B2 (ja) 1998-05-29 1999-05-28 アゴニストまたはアンタゴニストホルモン特性を有する１７β−アミノおよびヒドロキシルアミノ−１１β−アリルステロイドとその誘導体

Country Status (25)

Country Link
US (3) US6262042B1 (US06262042-20010717-C00011.png)
EP (1) EP1082337B1 (US06262042-20010717-C00011.png)
JP (1) JP4545929B2 (US06262042-20010717-C00011.png)
KR (1) KR100611289B1 (US06262042-20010717-C00011.png)
CN (1) CN100357311C (US06262042-20010717-C00011.png)
AT (1) ATE333462T1 (US06262042-20010717-C00011.png)
AU (1) AU753382B2 (US06262042-20010717-C00011.png)
BR (1) BR9910794A (US06262042-20010717-C00011.png)
CA (1) CA2333669C (US06262042-20010717-C00011.png)
CY (1) CY1106443T1 (US06262042-20010717-C00011.png)
CZ (1) CZ300313B6 (US06262042-20010717-C00011.png)
DE (1) DE69932432T8 (US06262042-20010717-C00011.png)
DK (1) DK1082337T3 (US06262042-20010717-C00011.png)
ES (1) ES2270596T3 (US06262042-20010717-C00011.png)
HK (1) HK1035196A1 (US06262042-20010717-C00011.png)
HU (1) HU228770B1 (US06262042-20010717-C00011.png)
ID (1) ID26885A (US06262042-20010717-C00011.png)
IL (1) IL139861A (US06262042-20010717-C00011.png)
NO (1) NO317988B1 (US06262042-20010717-C00011.png)
NZ (1) NZ507985A (US06262042-20010717-C00011.png)
PL (1) PL198055B1 (US06262042-20010717-C00011.png)
PT (1) PT1082337E (US06262042-20010717-C00011.png)
RU (1) RU2238943C2 (US06262042-20010717-C00011.png)
SK (1) SK285748B6 (US06262042-20010717-C00011.png)
WO (1) WO1999062928A1 (US06262042-20010717-C00011.png)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262042B1 (en) * 1998-05-29 2001-07-17 Research Triangle Institute 17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
ES2190373B1 (es) * 2001-12-07 2004-10-16 J. URIACH & CIA, S.A. Uso del acido 2-hidroxi- o 2-acetiloxi-4-trifluorometilbenzoico como agente para el tratamiento y prevencion del deterioro cognitivo ligero.
CN100439361C (zh) 2003-03-07 2008-12-03 先灵公司 取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
EP1601669B1 (en) 2003-03-07 2008-12-24 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US8097606B2 (en) * 2003-07-23 2012-01-17 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of catatonia
US20070249573A1 (en) * 2006-04-13 2007-10-25 Gerd Schubert 17alpha-substituted 4-(3-oxoestra-4,9-dien-11beta-yl)-benzoic acid, its derivatives and process for its production
US9517240B2 (en) 2006-09-26 2016-12-13 The Regents Of The University Of California Methods and compositions for cancer prevention and treatment
US20100160275A1 (en) * 2006-09-26 2010-06-24 Lee Eva Y H P Methods and compositions for cancer prevention and treatment
US8299050B2 (en) * 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
US8778969B2 (en) * 2009-11-07 2014-07-15 Peter H Proctor Nitrone, nitroso, and nitroxide spintraps and spin labels and their hydroxylamines
US9096641B2 (en) * 2013-06-05 2015-08-04 Evestra, Inc. Imidazolyl progesterone antagonists

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE289539C (US06262042-20010717-C00011.png)
DE287510C (US06262042-20010717-C00011.png)
DE290198C (US06262042-20010717-C00011.png)
US3187022A (en) * 1964-01-31 1965-06-01 Parke Davis & Co 17beta-amino-17alpha-pregnen-20-one compounds and the production thereof
US4686085A (en) * 1980-04-14 1987-08-11 Thomas Jefferson University Stroke treatment utilizing extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders
ZA8231B (en) 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2522328B1 (fr) 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
DE3306121A1 (de) * 1983-02-18 1984-09-06 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-spirolaktone in der steroidreihe, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische praeparate
EP0116974B1 (de) * 1983-02-18 1986-10-29 Schering Aktiengesellschaft 11-Beta-Aryl-Estradiene, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Präparate
DE3347126A1 (de) 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
US4481144A (en) 1984-02-03 1984-11-06 E. R. Squibb & Sons, Inc. 17-Substituted thia-17-alkyl(or alkenyl or alkynyl)androstenes
US4529548A (en) 1984-05-07 1985-07-16 E. R. Squibb & Sons, Inc. 17β-(substituted thio)androstenes
NZ214998A (en) 1985-02-07 1989-06-28 Schering Ag 13-(methyl or ethyl)-11-beta-phenyl-gonane derivatives; preparatory processes and pharmaceutical compositions
DE3506785A1 (de) 1985-02-22 1986-08-28 Schering AG, Berlin und Bergkamen, 1000 Berlin 11ss-n,n-dimethylaminophenyl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2596395B1 (fr) 1986-03-26 1989-05-26 Roussel Uclaf Nouveaux steroides comportant un cycle spirannique en position 17, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
FR2598421B1 (fr) 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
DE3625315A1 (de) 1986-07-25 1988-01-28 Schering Ag 11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate
US4861763A (en) 1986-09-17 1989-08-29 Research Triangle Institute 17 α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and their progestational use
US4774236A (en) 1986-09-17 1988-09-27 Research Triangle Institute 17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them
DE3702383A1 (de) 1987-01-23 1988-08-04 Schering Ag 11ss-alkinylestrene und -estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
IE60780B1 (en) 1987-01-23 1994-08-10 Akzo Nv New 11-aryl steroid derivatives
FR2610933B1 (fr) 1987-02-18 1989-06-09 Roussel Uclaf Nouveaux 19-nor steroides substitues en position 7, leur preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant
ATE69820T1 (de) 1987-04-24 1991-12-15 Akzo Nv 11-arylestranderivate und 11-arylpregnanderivate.
FR2618783B1 (fr) 1987-07-30 1991-02-01 Roussel Uclaf Nouveaux 17-aryle steroides, leurs procedes et des intermediaires de preparation comme medicaments et les compositions pharmaceutiques les renfermant
DE3878198T2 (de) 1987-12-12 1993-06-24 Akzo Nv 11-arylsteroid-derivate.
US4954490A (en) * 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
DE3822770A1 (de) 1988-07-01 1990-01-04 Schering Ag 13-alkyl-11ss-phenylgonane
FR2643638B1 (fr) 1989-02-24 1991-06-14 Roussel Uclaf Nouveaux 19-nor steroides ayant en position 11beta une chaine carbonee comportant une fonction amide ou carbamate, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant
ATE137074T1 (de) 1989-06-20 1996-05-15 Philips Electronics Nv Signalverarbeitungseinrichtungen vor und nach übertragung und/oder speicherung mit datenflussverminderung, und verfahren zur übertragung und/oder speicherung von signalen mit solchen einrichtungen
DE3921059A1 (de) 1989-06-23 1991-01-10 Schering Ag 11(beta)-aryl-4-estrene, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel
ATE172469T1 (de) 1989-08-04 1998-11-15 Schering Ag 11 beta-aryl-gona-4,9-dien-3-one
DE4042005A1 (de) 1990-12-22 1992-06-25 Schering Ag D-homo-(16-en)-11(beta)-aryl-4-estrene
ZA929315B (en) 1991-12-20 1993-05-24 Akzo Nv 17-spirofuran-3'-ylidene steroids.
MX9301121A (es) 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
WO1993021926A1 (en) 1992-05-06 1993-11-11 Medical College Of Hampton Roads Minimizing progestin associated breakthrough bleeding
US5929262A (en) 1995-03-30 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
CA2253673C (en) 1996-05-01 2009-09-08 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services 21-substituted progesterone derivatives as new antiprogestational agents
US6020328A (en) 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US5962444A (en) 1998-05-29 1999-10-05 Research Triangle Institute 17β-nitro-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6262042B1 (en) 1998-05-29 2001-07-17 Research Triangle Institute 17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6172052B1 (en) 1998-12-04 2001-01-09 Research Triangle Institute 17β-acyl-17α-propynyl-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6043235A (en) 1999-07-21 2000-03-28 Research Triangle Institute 11β-aryl-17, 17-spirothiolane-substituted steroids

Also Published As

Publication number Publication date
KR100611289B1 (ko) 2006-08-10
PL344413A1 (en) 2001-11-05
SK285748B6 (sk) 2007-07-06
IL139861A0 (en) 2002-02-10
CA2333669A1 (en) 1999-12-09
HK1035196A1 (en) 2001-11-16
KR20010052427A (ko) 2001-06-25
JP2002531381A (ja) 2002-09-24
PT1082337E (pt) 2006-11-30
HU228770B1 (en) 2013-05-28
EP1082337A1 (en) 2001-03-14
ES2270596T3 (es) 2007-04-01
NZ507985A (en) 2003-11-28
SK18092000A3 (sk) 2001-04-09
EP1082337B1 (en) 2006-07-19
NO20005989L (no) 2000-11-27
RU2238943C2 (ru) 2004-10-27
NO317988B1 (no) 2005-01-17
HUP0103109A2 (hu) 2002-01-28
EP1082337A4 (en) 2004-12-29
DK1082337T3 (da) 2006-12-04
NO20005989D0 (no) 2000-11-27
CZ20004446A3 (cs) 2001-04-11
US7018991B2 (en) 2006-03-28
CN1303391A (zh) 2001-07-11
ATE333462T1 (de) 2006-08-15
CA2333669C (en) 2008-08-26
CY1106443T1 (el) 2011-10-12
PL198055B1 (pl) 2008-05-30
ID26885A (id) 2001-02-15
HUP0103109A3 (en) 2002-09-30
DE69932432D1 (de) 2006-08-31
WO1999062928A1 (en) 1999-12-09
AU4076199A (en) 1999-12-20
DE69932432T8 (de) 2007-08-23
US20020065257A1 (en) 2002-05-30
CZ300313B6 (cs) 2009-04-15
IL139861A (en) 2005-09-25
DE69932432T2 (de) 2007-03-15
AU753382B2 (en) 2002-10-17
US20040023936A1 (en) 2004-02-05
US6262042B1 (en) 2001-07-17
BR9910794A (pt) 2001-02-13
CN100357311C (zh) 2007-12-26
US6620801B2 (en) 2003-09-16

Similar Documents

Publication Publication Date Title
CA2322862C (en) 20-keto-11.beta.-arylsteroids and their derivatives having agonist or antagonist hormonal properties
JP4545930B2 (ja) アゴニストまたはアンタゴニストホルモン特性を有する１７β−ニトロ−１１β−アリルステロイドとその誘導体
JP4545929B2 (ja) アゴニストまたはアンタゴニストホルモン特性を有する１７β−アミノおよびヒドロキシルアミノ−１１β−アリルステロイドとその誘導体
US6740645B1 (en) 17β-acyl-17α-propynyl-11β-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties
CA2614667C (en) 20-keto-11.beta.-arylsteroids and their derivatives having agonist or antagonist hormonal properties
MXPA00011769A (en) 17&bgr;-AMINO AND HYDROXYLAMINO-11&bgr;-ARYLSTEROIDS AND THEIR DERIVATIVES HAVING AGONIST OR ANTAGONIST HORMONAL PROPERTIES

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060509

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100216

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100601

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100701

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130709

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term